SF0034 is a novel compound designed to activate KCNQ2/3 potassium channels. This activation has shown promise in preclinical studies for treating epilepsy and preventing tinnitus. Research has shown that SF0034 effectively suppressed epileptic activity and prevented tinnitus development in animal models. In vitro studies have indicated that SF0034 is more potent than retigabine, a previously approved epilepsy medication, in activating KCNQ2/3 channels. Additionally, SF0034 has been shown to rescue current amplitudes in mutated channels associated with KCNQ2 encephalopathy, suggesting its potential as a therapeutic agent for this condition.
MedKoo Cat#: 145776
Name: SF-0034
CAS#: 1477492-01-5
Chemical Formula: C16H17F2N3O2
Exact Mass: 321.1300
Molecular Weight: 321.33
Elemental Analysis: C, 59.81; H, 5.33; F, 11.82; N, 13.08; O, 9.96
The following data is based on the product molecular weight 321.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
